AIM-HI Accelerator Fund is a non-profit organization that funds start-up oncology companies and supports innovative laboratory breakthroughs in cancer research. The fund aims to translate scientific discoveries into high-impact cancer treatments and STEM technologies.

AIM-HI Accelerator Fund

The AIM-HI Accelerator Fund is an independent 501(C)(3) non-profit organization, established with an initial grant from the National Foundation for Cancer Research with the vision to accelerate the translation of cancer drug discoveries by investing in seed-stage companies. It is a new paradigm through venture philanthropy to fund start-up oncology companies that commercialize innovative laboratory breakthroughs which can potentially save cancer patients’ lives.

The AIM-HI Accelerator Fund is thrilled to announce that Margaret Foti, Ph.D., M.D. (hc), Chief Executive Officer of the American Association for Cancer Research (AACR), is the recipient of the 2024 Beacon Award for Women Leaders in Oncology. Congratulations, Dr. Foti!
 
“As the CEO & Co-Founder of the AIM-HI Accelerator Fund, CEO of the National Foundation for Cancer Research, I have the unique privilege to work alongside some of the most accomplished, innovative, and respected leaders in cancer research and the fields of oncology. Dr. Foti epitomizes the attributes of impactful leadership and everything we at AIM-HI and NFCR seek to recognize in a Beacon Award recipient. I have known of the unwavering work of Dr. Foti for many years and have high respect for the impacts she has made on cancer research, science, and patient care worldwide,” said Dr. Sujuan Ba, Ph.D., President and CEO of the AIM-HI Accelerator Fund and National Foundation for Cancer Research and Co-Chair of the 2024 Beacon Award Selection Committee. 
 
“I am deeply honored to be named the 2024 Beacon Award for Women Leaders in Oncology recipient. This recognition is a testament to the relentless dedication and groundbreaking work of our members and entire team at AACR, as well as our partners in the cancer research community. Together, we are committed to accelerating the pace of scientific discovery and translating these findings into effective treatments that improve the lives of patients worldwide. This award inspires us to continue pushing the boundaries of innovation and collaboration in our ongoing fight against cancer. I would like to thank the Beacon Award Selection Committee and extend my heartfelt gratitude to AIM-HI Accelerator Fund and the National Foundation for Cancer Research for this prestigious acknowledgment and for their unwavering support of cancer research,” said Margaret Foti, Ph.D., M.D. (h.c.), Chief Executive Officer of the American Association for Cancer Research.
 
Dr. Foti will be honored as the 2024 AIM-HI Beacon Award recipient at a luncheon ceremony at the National Press Club in Washington, DC, on October 18, 2024. The award ceremony is part of the 2024 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship. 

2024 Beacon Award Selection Committee:
Sujuan Ba, Ph.D., Co-Chair
Webster Cavenee, Ph.D., Co-Chair
Bahija Jallal, Ph.D.
Raju Kucherlapati, Ph.D.
Patricia Obermaier, MBA
Libia F. Scheller, PhD, MBA
Thea Tlsty, Ph.D.

The Past Beacon Award Recipients:
Anna Barker, Ph.D., 2022 Awardee
Monica Bertagnolli, M.D., 2023 Awardee

Read the Press Release: https://bit.ly/3yu0eK8
Join us in honoring Dr. Margaret Foti: https://bit.ly/3ywm0gc

#AIMHIAccelerator #WomenInOncology #BeaconAward #Leadership #WomenLeaders #AwardCeremony #GlobalSummit

Exciting update from our portfolio company! Imran Alibhai, CEO of Tvardi Therapeutics, will participate in a fireside chat at the 2024 BTIG Virtual Biotechnology Conference on Tuesday, August 6, 2024, at 10:00 AM ET. 

In addition to the fireside chat, the Tvardi Therapeutics management team will also be holding one-on-one investor meetings on Monday and Tuesday, August 5-6, 2024. 

Don't miss this opportunity to learn about their latest technology in the development of STAT3 inhibitors and more! For details about the event, please read at: https://bit.ly/4dsGBkp or contact ir@tvardi.com directly!

#AIMHIAccelerator #Biotechnology #STAT3 #BTIGConference #Investment #Innovation

Exciting news! FREE Registration is now open for the 2024 Technology Showcase hosted by the National Cancer Institute (NCI) and the Frederick National Laboratory for Cancer Research. Don't miss out on this opportunity to join for a valuable session with the following benefits:

·       Free, in-person event
·       One-on-one partnering and networking opportunities.
·       NCI and FNL inventors highlight technologies for commercialization and/or collaboration.
·       How to partner with the NCI and the FNL including from the perspective of companies
·       Keynote speaker: Steven Walker, Chairman, Maryland Life Sciences
·       Panel sessions feature collaboration success stories, and topics relevant to commercializing biomedical technology.
·       Technology pitch and poster session highlights additional NIH technologies for collaborative development and/or licensing presented by the NCI Technology Transfer Ambassador Program.

Don't miss out on this exciting event! Scan the QR code or register at: https://bit.ly/4fcKJGK

#AIMHIAccelerator #TechShowcase #CancerResearch #Innovation #Entrepreneurship #TechAdvancements

🎊The 2024 BRACE Award Venture Competition launched the “People's Choice for Best Pitch” voting campaign, inviting the public audience to participate and vote for their favorite pitch from our seven semi-finalists.

We are excited to announce that the “People's Choice for Best Pitch” goes to Minh-Duy Phan, CEO & Scientific Co-Founder of NexCalibur Therapeutics! His presentation effectively explained NexCalibur's personalized, affordable neoantigen-based immunotherapy and its potential in treating cancer patients, particularly within the Asian population. Congratulations to Minh-Duy and the NexCalibur team! 

Who will be the top finalists selected by the 2024 Venture Competition judging committee? Stay tuned to find out! https://lnkd.in/eMkxKvcm

#AIMHIaccelerator #AFCR #BRACEAwardVentureCompetition #NeoantigenTherapy #PersonalizedMedicine #BiotechStartups

🎊 The 2024 Women’s Venture Competition launched the “People's Choice for Best Pitch” voting campaign, inviting the public audience to participate and vote for their favorite pitch from our seven semi-finalists.

We are excited to announce that the “People's Choice for Best Pitch” goes to Oriana Papin-Zoghbi, CEO & Co-Founder of AOA Dx! Her compelling presentation introduced AOA’s groundbreaking novel technology for the early diagnosis of ovarian cancer, raising awareness about the importance of early cancer detection through the use of biomarkers. Congratulations to Oriana and the AOA team! 

Who will be the top finalists selected by the 2024 Women’s Venture Competition judging committee? Stay tuned to find out! https://lnkd.in/duHNVZQx

#AIMHIaccelerator #WomensVentureCompetition #EmpoweringWomenInOncology #EmpoweringWomenEntrepreneurs #EarlyCancerDetection #OvarianCancer

AIM-HI wants to share an exciting opportunity with our community!

Springboard Enterprises is now accepting applications for their 2024 Healthcare and Technology Program! This program is designed to empower women-led companies by providing growth funding and expert connections to innovate in healthcare and technology.

If you are a woman entrepreneur or leading an innovative startup, don’t miss this chance! Submit your application by July 15th, 2024 at https://bit.ly/4b5jmvi

#AIMHIAccelerator #WomenInTech #HealthcareInnovation #Entrepreneurship #ApplyNow

The poll for the 2024 BRACE Award Venture Competition closes this Friday. Be sure to vote for your favorite early-stage oncology company for the People’s Choice award before the deadline at https://bit.ly/3R203Me

Watch the video to see these biotech leaders share their innovative technologies. Your donation to support this program will enable us to fund more groundbreaking research and development initiatives, bringing new hope and treatment options to cancer patients worldwide!  https://lnkd.in/dAq5G7P

#AIMHIAccelerator #BRACEAward #VentureCompetition #BioTechLeaders #CancerResearch #InnovativeTechnologies #CancerInnovation #SupportResearch #PeopleChoiceAward Stacy Blain Concarlo Therapeutics Minh-Duy Phan NexCalibur Therapeutics Scott Thacher Orphagen Pharmaceuticals

https://lnkd.in/eWpreSQX

There is still time to vote for your favorite woman scientist-entrepreneur for the People’s Choice Award. We can’t all be on the official Judging Committee, but we can ALL cast our vote! Remember to vote by this Friday at https://bit.ly/4dRKGj7

Watch the video as these pioneering women scientist-entrepreneurs share their innovative technologies. Stay tuned for more updates on the 2024 Women’s Venture Competition as we continue to support these groundbreaking startups on their journey to revolutionize cancer care. Your donation to this program will enable us to fund more women entrepreneurs and their life-saving oncology innovations: https://lnkd.in/dAq5G7P

#AIMHIAccelerator #VentureCompetition #CancerResearch #FundingInnovation #WomenInSTEM #WomenEntrepreneurs #EmpowerWomen Oriana Papin-Zoghbi AOA Dx Nabanita Nawar, PhD Pimyupa Manaswiyoungkul, PhD HDAX Therapeutics Deborah Charych, Ph.D. Paraskevi (Evi) Giannakakou

https://lnkd.in/e7t2hiBU

AIM-HI congratulates the semi-finalists of our 2024 Women’s Venture Competition, showcasing four innovative and aspiring women scientist-entrepreneurs. 

We also invite you to participate in selecting the People’s Choice Award for Best Pitch. Who will it be? Vote for your favorite woman scientist-entrepreneur by Friday, June 14, 2024, at https://bit.ly/4dRKGj7, or scan the QR code below.

#AIMHIAccelerator #WomenInScience #VentureCompetition #Entrepreneurship #OncologyInnovation #VoteNow

AIM-HI congratulates the 2024 BRACE Award Venture Competition semi-finalists, led by three aspiring scientist-entrepreneurs.

As part of the BRACE Award Venture Competition, we are looking to name one of our incredible semi-finalists as the People’s Choice Award for Best Pitch. Who will it be? We can’t all be on the official BRACE Award Judging Committee, but we can ALL cast our votes! 

Vote for your favorite early-stage oncology company by Friday, June 14, 2024, at https://bit.ly/3R203Me, or scan the QR code below.

#AIMHIAccelerator Asian Fund for Cancer Research #BRACEAward #Entrepreneurship #OncologyInnovation #VoteNow

Metric
Company Name	AIM-HI Accelerator Fund
Symbol
MSH ID	ORG:AIM-HIACCELERATOR
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology and Medical Research
Country	US
Stage
Employee Count
Website	aim-hiaccelerator.org
LinkedIn	aim-hi-accelerator-fund
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

AIM-

ORG:AIM-HIACCELERATOR

AIM-HI Accelerator Fund

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue